Dienogest versus continuous oral levonorgestrel/EE in patients with endometriosis: what's the best choice?
I Piacenti, MF Viscardi, L Masciullo… - Gynecological …, 2021 - Taylor & Francis
Objective Combined oral contraceptives (COC) and progestogens are widely used for the
treatment of endometriosis. The objective of the study is to compare the efficacy of dienogest …
treatment of endometriosis. The objective of the study is to compare the efficacy of dienogest …
[PDF][PDF] Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to …
J Dinger, S Möhner, K Heinemann - Front Womens Health, 2020 - zeg-berlin.de
Objectives: The previously reported initial results of the International Active Surveillance
study “Safety of Contraceptives: Role of Estrogens”(INAS-SCORE) suggested that the risks …
study “Safety of Contraceptives: Role of Estrogens”(INAS-SCORE) suggested that the risks …
Estradiol valerate vs ethinylestradiol in combined oral contraceptives: effects on the pituitary-ovarian axis
A Haverinen, K Luiro, MH Kangasniemi… - The Journal of …, 2022 - academic.oup.com
Context Limited studies have compared the effects of combined oral contraceptives (COCs)
containing natural estrogens and synthetic ethinylestradiol (EE) on reproductive hormones …
containing natural estrogens and synthetic ethinylestradiol (EE) on reproductive hormones …
Thromboembolierisiko unter kombinierten hormonellen Kontrazeptiva–aktueller Stand und Verschreibungspraxis
D Wunder - Praxis, 2023 - econtent.hogrefe.com
Die Anwendung kombinierter hormoneller Kontrazeptiva (KHK) erhöht das Risiko nicht nur
für venöse Thromboembolien (VTE), sondern auch für arterielle Thromboembolien (ATE) …
für venöse Thromboembolien (VTE), sondern auch für arterielle Thromboembolien (ATE) …
[HTML][HTML] Hormonal therapies and venous thrombosis: considerations for prevention and management—a reappraisal
We appreciate the response of LaVasseur et al.[1] to our Letter to the Editor on their article
on the risk of venous thromboembolism (VTE) with hormonal therapies, in which they remark …
on the risk of venous thromboembolism (VTE) with hormonal therapies, in which they remark …
[HTML][HTML] Repeated use of prescription drugs in pediatrics: comprehensive overview based on German claims data
O Scholle, A Neubert, O Riedel, I Toni… - Frontiers in …, 2021 - frontiersin.org
Background: Investigating drug utilization in large and unselected samples of children and
adolescents is an important component of public health monitoring. Most existing studies in …
adolescents is an important component of public health monitoring. Most existing studies in …
Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: sub-analysis of a prospective cohort study
D Tormene, E Campello, C Simion, A Poretto… - … and Vascular Biology, 2022 - btvb.org
Antithrombin, protein C and S defects are well-recognized inherited risk factors for venous
thromboembolism (VTE). Although these defects have been reported to increase the risk of …
thromboembolism (VTE). Although these defects have been reported to increase the risk of …
Risk of venous thromboembolism from use of Dienogest: Experimental study on Rats
HA Alsarraje, M Merkhan - Egyptian Journal of Histology, 2023 - ejh.journals.ekb.eg
Background and objective: We aimed to identify the effects of dienogest on inducing
thromboembolism in rats following exposure to dienogest for a period of either 10 days (2 …
thromboembolism in rats following exposure to dienogest for a period of either 10 days (2 …
Thromboembolism risk with combined hormonal contraceptives: current status and prescribing practice
D Wunder, G Merki-Feld - Gynäkologische Endokrinologie, 2021 - Springer
Zusammenfassung Die Anwendung kombinierter hormoneller Kontrazeptiva (KHK) erhöht
das Risiko nicht nur für venöse Thromboembolien (VTE), sondern auch für arterielle …
das Risiko nicht nur für venöse Thromboembolien (VTE), sondern auch für arterielle …
[PDF][PDF] Gynäkologische Anwendungen von Dienogest alleine und in Kombination mit Östrogenen
V Bartsch, T Römer - Journal of Medical Drug Reviews, 2020 - jmdrev.com
Dienogest ist ein hybrides synthetisches Gestagen, das Gemeinsamkeiten mit den 19-
Nortestosteron-und Progesteronderivaten aufweist, aber auch durch vorteilhafte …
Nortestosteron-und Progesteronderivaten aufweist, aber auch durch vorteilhafte …